AACR 2023 | The pharmacodynamics of the pan-MYC inhibitor OMO-103

Laura Soucek, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, describes the pharmacodynamics of OMO-103, a first-in-class direct MYC inhibitor. The half life and concentration of the drug was found to be extended in tumor tissue compared to blood serum by a factor of 4, demonstrating the potential efficacy of OMO-103. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.